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1. Introduction 
Familial hyperlipoproteinemia type III is a primary 
disorder of lipid metabolism characterized by an ele- 
vation of cholesterol and triglycerides in plasma and 
by the occurrence of an atypical lipoprotein in the 
VLDL fraction of affected individuals. This lipoprotein 
has fl- instead of pre-/J-mobility in electrophoresis [I] 
and is rich in cholesterol [2] and in an arginine-rich 
apolipoprotein [3]. There is evidence that this lipo- 
protein is an intermediate in the catabolism of trigly- 
ceride-rich lipoproteins which accumulate in hyper- 
lipoproteinemia type III [3]. 
The disease is associated with premature arterios- 
clerosis, but is usually not expressed before the age of 
twenty. The primary biochemical lesion in the fami- 
lial disorder is not known and there is uncertainty on 
its mode of inheritance [ 1,451. 
In the present study we have shown that one pro- 
tein component of mol. wt - 39 000 is deficient in 
the VLDL from patients with hyperlipoproteinemia 
type III. This most likely is the underlying defect in 
the hereditary dyslipoproteinemia. 
2. Materials and methods 
Fasting plasma was obtained from eight patients 
with hyperlipoproteinemia type III, five first degree 
Abbreviations: VLDL: Very-low-density lipoproteins (d < 
1.006 g/ml). LDL-1: Low-density-lipoproteins-l (d = 1.006- 
1.019 g/ml). LDL-2: Low-density-lipoproteins-2 (d = 1.019- 
1.063 g/ml). HDL: High-density-lipoproteins (d = 1.063-1.21 
g/ml). PAGE: Polyacrylamide gel electrophoresis. SDS: 
Sodium dodecyl suphate. 
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relatives of type III probands, who had type IV or 
type II hyperlipoproteinemia, sixteen normolipidemic 
blood donors, twenty patients with type IV and one 
with type V hyperlipoproteinemia. The diagnosis of 
type III hyperlipoproteinemia was established by 
demonstration of primary hyperlipidemia, P-migrating 
VLDL and a cholesterol: triglyceride ratio in VLDL 
considerably higher than 0.2 (between 0.53 and 0.77 
in all the patients studied here) [6,7]. The eight type 
III patients were all from different families. A detailed 
description of these patients and their relatives will be 
published elsewhere [8]. Two of the type III patients 
have already been documented in previous publica- 
tions (E. M. = III, 19 in [9] and E. R. in [lo]) and 
familial involvement has been verified in both [8,10] . 
Lipoprotein fractions VLDL, LDL-1, LDL2 and 
HDL were isolated by sequential ultracentrifugation 
in a Spinco model L2-6.5 B preparative centrifuge 
according to standard procedures [ 111 with minor 
modifications [ 121. Electrophoretic analysis of lipo- 
proteins in agarose gels was done as described by van 
Melsen et al. [ 131. Soluble lipoproteins were delipi- 
dated by five successive xtractions with 50 volumes 
of acetonethanol 1: 1 (v/v) at -15°C and finally dried 
with nitrogen [ 141. The arginine-rich apolipoprotein 
E and the C apoproteins were isolated from apo VLDL 
by preparative SDS-PAGE in the discontinous system 
of acetone-ethanol 1: 1 (v/v) at - 15°C and finally dried 
Analytical SDS-PAGE was performed according to 
Weber and Osborne [ 161 using a 10% monomer con- 
centration. Analytical isoelectric focusing of the urea 
soluble apo VLDL polypeptides was done by an adap- 
tion [ 121 of the method of Wrigley [ 171. Scanning 
densitometry of the focusing gels was performed after 
staining with Coomassie brillant blue in a Vitatron 
North-Holland Publishing Company -Amsterdam 
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TLD. Standard curves for quantitative determinations The characteristic polypeptide composition of 
of Apo C and Ape E in the urea soluble fraction of VLDL as demonstrated by SDS-PAGE is shown in 
apo VLDL were established by running known fig. 1. There are three main components in this frac- 
amounts of pure apolipoproteins in parallel gels. tion: Apo B, Apo C and an arginine-rich protein we 
Protein was determined according to Lowry et al. have designated Apo E [ 141. The latter protein, 
[ 18 ] with 0.1% SDS in the reaction mixture, choles- which has an apparent mol. wt of -39 000 in SDS- 
terol by the procedure of Roes&au et al. [ 191 and PAGE, is heterogenous and shows three major com- 
triglycerides by the method of Eggstein and Kreutz ponents in analytical isoelectric focusing in the 
]201* presence of 6 M urea (fig. 1, [ 141). 
3. Results and discussion 
In a search for the primary metabolic defect in 
familial hyperlipoproteinemia type III, we have studied 
the polypeptide composition of VLDL in patients with 
hyperlipoproteinemia type III, first degree relatives of 
type III probands with and without other phenotypic 
expressions of dyslipoproteinemia and for comparison 
a control group comprising of normolipidaemic volun- 
teers and of patients with type IV and V hyperlipopro- 
teinemia. 
a b 
,+ 
Fig. 1. (Left) SDS-PAGE of apo VLDL (a) and purified Apo 
E (b). (Right) Analytical isoelectric focusing of urea soluble 
apo VLDL in polyacrylamide gels at pH 3.5-10 (c) and the 
same apo E preparation as in gel b (d). 
The three Apo E polypeptides were demonstrated 
in a ratio of roughly 2: 1: 2 in the apo VLDL of all the 
thirty-seven controls. Quantitatively Apo E repre- 
sented 18% of the urea soluble fraction of normo- 
lipidaemic subjects (table 1) and about 10% of the 
total apo VLDL [14]. On the other hand, none of 
type III patients demonstrated this normal apo VLDL 
focusing pattern. Two deviations from normal were 
evaluated by inspection and standardizing scanning 
densitometry of the stained gels (fig.2, table 1). 
First the percentage of apo,E in the urea soluble apo 
VLDL was on the average 57% which is considerably 
higher than in the controls. This finding is in general 
agreement with previous results of Have 1 and Kane 
[3]. Despite the predominance of the arginine-rich 
Apo E in this fraction, none of the eight type III 
probands showed significant amounts of a protein 
preliminary designated Apo E-III ( [ 141 fig. 1,2) 
which was present in all the controls. 
Apo E-III could not be detected in any of the 
other lipoprotein fractions of the patients and seems 
thus to be deficient in their lipoprotein system. Only 
traces of Apo E were detected in the HDL and LDL2 
of the type III patients by SDS-PAGE or isoelectric 
focusing. Their LDLl, however, contained particles 
of P-mobility which were extremely rich in total Apo 
E, but the specific Apo E-III was also deficient in this 
fraction (fig.3). 
The catabolism of triglyceride-rich lipoproteins 
proceeds through different steps [21] . One of these 
is apparently impaired in familial type III hyperlipo- 
proteinemia, resulting in the accumulation of the 
intermediate &VLDL [3]. Recent evidence along 
with that presented here suggests that Apo E is 
intimately associated with the conversion of trigly- 
ceride-rich to cholesterol ester-rich lipoproteins and 
is primarily involved in the transport and metabolism 
of cholesterol [3,8,22-241. The specific function 
of the arginine-rich Apo E in this process is not yet 
353 
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Table 1 
August 1975 
Characteristics of VLDL fractions from patients with primary hyperlipoproteinemia type III 
Patient phenotype C/TG Mobility 
prae-(3’ p 
Urea soluble apoproteins Apo E 
(weight %) (% of densitometric area) 
Apo C Apo E E-I E-II E-III 
H. Sch. III 0.53 + + 60 40 42 58 - 
E. R. III 0.53 + + 27 73 41 59 - 
E. M. III 0.66 + + 44 56 42 58 - 
Ch. J. III 0.55 + + 41 59 51 49 - 
s. J. III 0.77 + + 45 55 42 58 - 
Mean k SD 0.63 f 0.09 43 + 12 57 +12 43.6 f 4.4 56.4 24.4 - 
Controla N 0.24 + - 82 18 38 23 39 
C/TG = Cholesterol/Triglyceride ratio 
aVLDL isolated from a pool of 12 normolipidemic blood donors. 
understood. The data known on the metabolic role 
of Apo E, however, is compatible with the hypothesis 
that a defect in the regulation or structure of Apo 
E-III is responsible for the hereditary human disease 
hyperlipoproteinemia type III. 
Fig.2. Analytical isoelectric focusing in polyacrylamide gels 
at pH 3.5-10 of apo VLDL from patients E. M. (a), H.Sch. 
(c) and E. R. (e) with familial hyperlipoproteinemla type III, 
the son’0. M. of proband E. M. who had a type IV pattern 
(b) and controls (d,f). 
354 
The data presented here suggest hat Apo E-III 
deficiency is a genuine marker for familial broad+ 
disease. This marker may help to establish the diag- 
nosis in uncertain cases and allows to differentiate 
secondary forms [8] . 
Apo E-III was not deficient in the apo VLDL from 
first degree relatives of type III probands, who had 
Fig.3. SDS-PAGE (left) and analytical isoelectric focusing at 
pH 3.5-10 (right) of urea-soluble apo CDL-1 proteins from 
patient E. M. with hyperlipoproteinemia type III. 
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other phenotypic forms of hyperlipidemia (tig.2), 
and in both parents of one type III proband (E. R. ). 
The genetical aspects of these observations and a 
family study which is in progress in our laboratory 
will be discussed elsewhere in detail [8]. The prelim- 
inary results from the family study indicate that 
the deficiency of Apo E-III is transmitted by an 
autosomal recessive mode of inheritance and that 
patients with type III are homozygous for this defect. 
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